Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia

被引:39
作者
Bradley, Sophie J. [1 ]
Langmead, Christopher J. [2 ]
Watson, Jeannette M. [3 ]
Challiss, R. A. John [1 ]
机构
[1] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England
[2] Heptares Therapeut Ltd, Welwyn Garden City, Herts, England
[3] GlaxoSmithKline Inc, Neurosci Ctr Excellence Drug Discovery, Harlow, Essex, England
基金
英国生物技术与生命科学研究理事会;
关键词
METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-COUPLED RECEPTORS; KINASE-C PHOSPHORYLATION; CALCIUM OSCILLATIONS; ANTIPSYCHOTIC-LIKE; DRUG DISCOVERY; SUBTYPE-5; GLUTAMATE-RECEPTOR-5; PHARMACOLOGY; BINDING;
D O I
10.1124/mol.110.068882
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Positive and negative allosteric modulators (PAMs and NAMs, respectively) of the type 5 metabotropic glutamate (mGlu5) receptor have demonstrable therapeutic potential in an array of neurological and psychiatric disorders. Here, we have used rat cortical astrocytes to investigate how PAMs and NAMs mediate their activity and reveal marked differences between PAMs with respect to their modulation of orthosteric agonist affinity and efficacy. Affinity cooperativity factors (alpha) were assessed using [(3)H]2-methyl-6-(phenylethynyl)-pyridine (MPEP)-PAM competition binding in the absence and presence of orthosteric agonist, whereas efficacy cooperativity factors (beta) were calculated from net affinity/efficacy cooperativity parameters (alpha beta) obtained from analyses of the abilities of PAMs to potentiate [(3)H] inositol phosphate accumulation in astrocytes stimulated with a sub-maximal (EC(20)) concentration of orthosteric agonist. We report that whereas 3,3'-difluorobenzaldazine (DFB) and 3-cyano-N(1,3-diphenyl-1H-prazol-5-yl) benzamide (CDPPB) primarily exert their allosteric modulatory effects through modifying the apparent orthosteric agonist affinity at the astrocyte mGlu5 receptor, the effects of S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)[1,2,4]oxadiazol-5-yl]-piperidinl-1-yl}-methanone (ADX47273) are mediated primarily via efficacy-driven modulation. In [(3)H]MPEP-NAM competition binding assays, both MPEP and 2-(2-(3-methoxyphenyl) ethynyl)-5-methylpyridine (M-5MPEP) defined similar specific binding components, with affinities that were unaltered in the presence of orthosteric agonist, indicating wholly negative efficacy-driven modulations. It is noteworthy that whereas M-5MPEP only partially inhibited orthosteric agonist-stimulated [3H] inositol phosphate accumulation in astrocytes, it could completely suppress Ca(2+) oscillations stimulated by quisqualate or (S)-3,5-dihydroxyphenylglycine. In contrast, MPEP was fully inhibitory with respect to both functional responses. The finding that M-5MPEP has different functional effects depending on the endpoint measured is discussed as a possible example of permissive allosteric antagonism.
引用
收藏
页码:874 / 885
页数:12
相关论文
共 40 条
[1]   [3H]methoxymethyl-3-[(2-methylyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain:: In vitro and in vivo characterization [J].
Anderson, JJ ;
Rao, SP ;
Rowe, B ;
Giracello, DR ;
Holtz, G ;
Chapman, DF ;
Tehrani, L ;
Bradbury, MJ ;
Cosford, NDP ;
Varney, MA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1044-1051
[2]   Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia [J].
Biber, K ;
Laurie, DJ ;
Berthele, A ;
Sommer, B ;
Tölle, TR ;
Gebicke-Härter, PJ ;
van Calker, D ;
Boddeke, HWGM .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (04) :1671-1680
[3]   Distinct roles of group I mGlu receptors in striatal function [J].
Bonsi, P. ;
Platania, P. ;
Martella, G. ;
Madeo, G. ;
Vita, D. ;
Tassone, A. ;
Bernardi, G. ;
Pisani, A. .
NEUROPHARMACOLOGY, 2008, 55 (04) :392-395
[4]   Effects of Positive Allosteric Modulators on Single-Cell Oscillatory Ca2+ Signaling Initiated by the Type 5 Metabotropic Glutamate Receptor [J].
Bradley, Sophie J. ;
Watson, Jeannette M. ;
Challiss, R. A. John .
MOLECULAR PHARMACOLOGY, 2009, 76 (06) :1302-1313
[5]   N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors [J].
Chen, Yelin ;
Goudet, Cyril ;
Pin, Jean-Philippe ;
Conn, P. Jeffrey .
MOLECULAR PHARMACOLOGY, 2008, 73 (03) :909-918
[6]   Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses [J].
Chen, Yelin ;
Nong, Yi ;
Goudet, Cyril ;
Hemstapat, Kamondanai ;
de Paulis, Tomas ;
Pin, Jean-Philippe ;
Conn, P. Jeffrey .
MOLECULAR PHARMACOLOGY, 2007, 71 (05) :1389-1398
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]   Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders [J].
Conn, P. Jeffrey ;
Christopoulos, Arthur ;
Lindsley, Craig W. .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) :41-54
[9]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[10]   Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome [J].
Dolen, Gul ;
Bear, Mark F. .
JOURNAL OF PHYSIOLOGY-LONDON, 2008, 586 (06) :1503-1508